(Information provided by Commonwealth Pharmaceuticals, British West Indies, manufacturers of Reticulose)
Patients with Hepatitis A and 18 patients with Hepatitis B were treated with Reticulose. 9 Patients with Hepatitis A and 17 patients with Hepatitis B were controls and treated with placebo. The treated patients received Reticulose for a 15 day period, while the control received saline. Based upon laboratory findings of several parameters: Prothrombin times, Serum bilirubin, white blood cell count, and clinical observations, Reticulose treated patients appeared to show significant improvement. The bilirubin levels of 83% of patients with Hepatitis B, treated with Reticulose for 15 days were in the normal range in 30 days. None of the control patients treated with placebo were within normal range in 30 days. Of Hepatitis A patients treated with Reticulose, 100% showed normal bilirubin after 30 days. Of control patients with Hepatitis A, only 22% were in normal range after 30 days. The findings in this preliminary trial lead to the conclusion that Reticulose appears to significantly reduce the recovery time and return to normal for patients with an acute episode of Hepatitis A or B. Further study is indicated.
Conclusions: In this preliminary Human Clinical Trial in 53 patients with Hepatitis A or Hepatitis B, one half of whom were treated with Reticulose, the results demonstrated positive clinical and laboratory effects. 18 patients with Hepatitis B and 9 with Hepatitis A were treated with Reticulose, compared to 17 control patients with Hepatitis B and 9 control patients with Hepatitis A treated with placebo. Patients were diagnosed for Hepatitis A or B by appropriate laboratory tests of blood, urine, x-ray and physical examination, with special attention to Anti-HAV IGM and Hepatitis B surface Antigen to carefully differentiate those with A from those with B. We realize, however, that liver biopsy is the positive method for hepatitis diagnosis, but physical limitations prevented our using this method in this study. Based upon laboratory findings, serum bilirubin levels of 83% patients with Hepatitis B, treated with Reticulose for 15 days were in normal range in 30 days, 50% in 15 days, and 22% in 10 days. None of the control patients were in normal range after 30 days with placebo treatment. In the Hepatitis A patients treated with Reticulose, 100% showed normal bilirubin levels after 30 days, 89% after 15 days, and 33% after 10 days.
In the control patients with Hepatitis A only 22% were in normal range after 30 days, 11% after 15 days, and 11% after 10 days.
In all of the Reticulose treated patients, the white blood cell count showed significant increase, indicating stimulus to the immune system. In all of the Reticulose treated patients, the prothrombin times returned promptly to normal range while the controls did not. The results appear to demonstrate significant improvement in the patients treated with Reticulose, especially those with Hepatitis B. - “The use of Reticulose in the Treatment of Hepatitis A, B & C,” Excerpted from: Journal of the Royal Society of Health Volume 112, No. 6, pages 266-270 December, 1992
